IRLAB Therapeutics is focused on developing novel, potential first-in-class treatments for the symptoms of Parkinson’s disease (PD). PD is a complex and progressive neurodegenerative condition with huge unmet need. IRLAB has two lead assets in Phase II trials: mesdopetam (D3 antagonist) and pirepemat (PFC enhancer). Both assets have a unique MOA and were developed through its proprietary technology ISP platform to address a wide spectrum of symptoms such as levodopa-induced dyskinesias (PD-LIDs), psychosis and PD-Falls. Top-line data from the mesdopetam US/EU Phase IIb/III trial in PD-LIDs, expected in H122, will define the pivotal trials required for approval. We value IRLAB at SEK4.8bn.
